Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NOVRAD

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

Standard Dose
EQ 50MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview NOVRAD is listed in Drugs@FDA under application 012928 (NDA).

Marketing status: Discontinued Active ingredient LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS Form and strength CAPSULE;ORAL - EQ 50MG BASE Sponsor LILLY Submission history Latest submission status date: 1981-06-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview NOVRAD is listed in Drugs@FDA under application 012928 (NDA). Marketing status: Discontinued Active ingredient LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS Form and strength CAPSULE;ORAL - EQ 50MG BASE Sponsor LILLY Submission history Latest submission status date: 1981-06-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.